Arca
Skip to content
Tools
Tools

Hepatitis C virus genotype 1

Drug research and approvals for hepatitis C virus genotype 1: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 22, 2026, 0 studies of hepatitis C virus genotype 1 are recruiting on ClinicalTrials.gov, Health Canada has authorized 20 drug trials for it since 2013, and FDA has 1 approved and 0 open orphan designations naming it.

  • Recruiting worldwide: 0
  • Trials authorized in Canada: 20
  • FDA orphan approvals: 1
  • EU medicines: 0

Trials authorized in Canada

The 10 newest of 20; search them all in Canada trials
Oct 22, 2015An open-label, multicenter study to evaluate the pharmacokinetics, safety, and efficacy of ombitasvir (OBV), paritaprevir (PTV), ritonavir (RTV) with or…Paritaprevir (ABT-450)-ritonavir-ombitasvir (ABT-267)/ Dasabuvir (ABT-333)/…AbbViePending
Sep 30, 2015An open-label, single arm study to evaluate the safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir in treatment-naïve adults with genotype…Paritaprevir (ABT-450)-ritonavir-ombitasvir (ABT-267)/ Dasabuvir (ABT-333)AbbVieClosed
Sep 29, 2015The effects of anti-viral therapy on the clinical status, quality of life, and survival of patients with decompensated cirrhosis due to hepatitis C genotype 1…Ledipasvir-sofosbuvirToronto General HospitalClosed
Jul 10, 2015Open-label study to evaluate the safety and efficacy of the combination of ombitasvir, paritaprevir/r ± dasabuvir with ribavirin (RBV) in adult patients with…Paritaprevir (ABT-450)-ritonavir-ombitasvir (ABT-267)/ Dasabuvir (ABT-333)/…AbbVieClosed
Feb 4, 2015A phase 2, open-label study to investigate the efficacy, safety, tolerability and pharmacokinetics of 6 or 8 weeks of treatment with simeprevir, daclatasvir…Simeprevir / Sofosbuvir/ DaclatasvirJohnson & JohnsonClosed
Dec 18, 2014A phase II, randomized, open-label clinical trial to study the efficacy and safety of the combination regimen of MK-5172 and MK-3682 with either MK-8742 or…MK-3682/ MK-5172/ MK-8742/ MK-8408Merck & Co. (MSD)Closed
Sep 24, 2014An open-label, multicenter study to evaluate long-term outcomes with ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 with or without ribavirin (RBV)…Paritaprevir (ABT-450)-ritonavir-ombitasvir (ABT-267)/ Dasabuvir (ABT-333)/…AbbVieOngoing
Aug 26, 2014An open-label, single-arm study to evaluate the safety and efficacy of ombitasvir/ABT-450/ ritonavir and dasabuvir in adults with genotype 1b chronic hepatitis…ABT-450-ritonavir-ABT-267/ DasabuvirAbbVieClosed
Aug 13, 2014An open-label study to evaluate the safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin in adults with genotype 1 and…Paritaprevir (ABT-450)-ritonavir-ombitasvir (ABT-267)/ Dasabuvir (ABT-333)/…AbbVieClosed
Jul 23, 2014A multicenter, open-label, partially randomized, parallel-group, adaptive design, phase II study on efficacy and safety of DEB025/alisporivir in combination…Alisporivir (DEB025)/ Mericitabine (RO5024048)/ RibavirinNovartis PharmaceuticalsPending

FDA orphan designations

Approved first, then open designations, newest first
DateDrugSponsorStatus
Apr 7, 2017HarvoniTreatment of pediatric patients 12 years of age and older or weighing at least 35 kg with chronic hepatitis C virus genotype 1, 4, 5, or 6…Gilead Sciences, Inc.Approved

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.